KT-621

The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition.

Kymera Therapeutics is progressing KT-621, a STAT6 degrader, with Phase 1 data expected in Q2 2025 and Phase 1b trials in atopic dermatitis planned for Q2 2025.

Kymera Therapeutics initiates Phase 1 clinical trial for KT-621, a first-in-class oral STAT6 degrader, marking the first STAT6-targeted medicine in clinical development.

Kymera Therapeutics received FDA clearance for its IND application for KT-621, a first-in-class oral STAT6 degrader, marking a significant advancement in targeted protein degradation.